$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000154422717000014 Filed on November 02, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$90.00K	$56.00K	$197.0K
YoY Change	-25.0%	-71.57%	162.67%
Cost Of Revenue	$220.0K	$29.00K	$1.559M
YoY Change	-84.62%	-98.14%	65.85%
Gross Profit	-$130.0K	$27.00K	-$1.362M
YoY Change	-90.08%	-101.98%	57.46%
Gross Profit Margin	-144.44%	48.21%	-691.37%
Selling, General & Admin	$4.810M	$5.056M	$12.61M
YoY Change	-56.07%	-59.91%	-2.3%
% of Gross Profit		18725.93%
Research & Development	$3.560M	$4.016M	$4.990M
YoY Change	-24.42%	-19.52%	24.81%
% of Gross Profit		14874.07%
Depreciation & Amortization	$340.0K	$400.0K	$600.0K
YoY Change	-42.37%	-33.33%	100.0%
% of Gross Profit		1481.48%
Operating Expenses	$8.370M	$9.462M	$19.16M
YoY Change	-46.55%	-50.62%	7.36%
Operating Profit	-$8.500M	-$9.406M	-$18.96M
YoY Change	-49.91%	-50.4%	6.71%
Interest Expense	$190.0K	$50.00K	-$200.0K
YoY Change	-190.48%	-125.0%	11.11%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$3.000K	-$33.00K
YoY Change	-100.0%	-90.91%	-232.0%
Pretax Income	-$8.490M	-$9.356M	-$19.20M
YoY Change	-62.53%	-51.27%	7.13%
Income Tax	$30.00K	$11.00K	$92.00K
% Of Pretax Income
Net Earnings	-$8.530M	-$9.367M	-$19.29M
YoY Change	-62.32%	-51.44%	7.64%
Net Earnings / Revenue	-9477.78%	-16726.79%	-9792.39%
Basic Earnings Per Share
Diluted Earnings Per Share	-$53.31	-$58.56	-$120.60
COMMON SHARES
Basic Shares Outstanding	35.71M shares	35.69M shares	35.56M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$67.20M	$75.70M	$131.0M
YoY Change	-41.26%	-42.21%	-7.55%
Cash & Equivalents	$15.70M	$24.78M	$50.48M
Short-Term Investments	$51.50M	$51.00M	$80.50M
Other Short-Term Assets	$1.600M	$1.900M	$2.500M
YoY Change	-23.81%	-24.0%	-30.56%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$68.78M	$77.61M	$133.5M
YoY Change	-40.93%	-41.85%	-8.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.113M	$3.606M	$8.047M
YoY Change	-44.13%	-55.19%	19.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$146.0K	$0.00	$435.0K
YoY Change	124.62%	-100.0%	80.5%
Other Assets	$24.00K	$23.00K	$23.00K
YoY Change	4.35%	0.0%
Total Long-Term Assets	$4.072M	$4.418M	$8.944M
YoY Change	-33.23%	-50.6%	19.49%
TOTAL ASSETS
Total Short-Term Assets	$68.78M	$77.61M	$133.5M
Total Long-Term Assets	$4.072M	$4.418M	$8.944M
Total Assets	$72.85M	$82.03M	$142.4M
YoY Change	-40.55%	-42.4%	-6.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.242M	$2.691M	$2.770M
YoY Change	2.7%	-2.85%	-33.35%
Accrued Expenses	$5.562M	$6.212M	$8.500M
YoY Change	-49.56%	-26.92%	49.12%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.804M	$8.903M	$11.27M
YoY Change	-40.92%	-20.97%	14.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$751.0K	$834.0K	$1.300M
YoY Change	-32.71%	-35.85%	263.13%
Total Long-Term Liabilities	$751.0K	$834.0K	$1.300M
YoY Change	-32.71%	-35.85%	263.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.804M	$8.903M	$11.27M
Total Long-Term Liabilities	$751.0K	$834.0K	$1.300M
Total Liabilities	$8.555M	$9.737M	$12.52M
YoY Change	-40.28%	-22.23%	22.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$301.5M	-$293.0M	-$227.5M
YoY Change	20.51%	28.75%	54.45%
Common Stock	$36.00K	$36.00K	$36.00K
YoY Change	0.0%	0.0%	33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$64.30M	$72.29M	$129.9M
YoY Change
Total Liabilities & Shareholders Equity	$72.85M	$82.03M	$142.4M
YoY Change	-40.55%	-42.4%	-6.81%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$8.530M	-$9.367M	-$19.29M
YoY Change	-62.32%	-51.44%	7.64%
Depreciation, Depletion And Amortization	$340.0K	$400.0K	$600.0K
YoY Change	-42.37%	-33.33%	100.0%
Cash From Operating Activities	-$7.970M	-$10.30M	-$15.44M
YoY Change	-46.72%	-33.29%	23.32%
INVESTING ACTIVITIES
Capital Expenditures	$50.00K	$10.00K	$180.0K
YoY Change	-96.75%	-94.44%	-84.62%
Acquisitions
YoY Change
Other Investing Activities	-$1.060M	$11.78M	-$29.90M
YoY Change	-110.63%	-139.4%	417.3%
Cash From Investing Activities	-$1.100M	$11.76M	-$30.07M
YoY Change	-113.06%	-139.11%	332.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	100.0K
YoY Change	-100.0%	-100.0%	25.0%
NET CHANGE
Cash From Operating Activities	-7.970M	-10.30M	-15.44M
Cash From Investing Activities	-1.100M	11.76M	-30.07M
Cash From Financing Activities	0.000	0.000	100.0K
Net Change In Cash	-9.070M	1.460M	-45.41M
YoY Change	38.47%	-103.22%	134.19%
FREE CASH FLOW
Cash From Operating Activities	-$7.970M	-$10.30M	-$15.44M
Capital Expenditures	$50.00K	$10.00K	$180.0K
Free Cash Flow	-$8.020M	-$10.31M	-$15.62M
YoY Change	-51.39%	-33.99%	14.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35705722	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	OvaScience, Inc.
CY2016Q4	ovas	Accrued Legal Audit And Tax Services Current AccruedLegalAuditAndTaxServicesCurrent	1280000	USD
CY2017Q3	ovas	Accrued Legal Audit And Tax Services Current AccruedLegalAuditAndTaxServicesCurrent	810000	USD
CY2016Q4	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	888000	USD
CY2017Q3	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	357000	USD
CY2016Q4	ovas	Development Site Costs And Contract Manufacturing DevelopmentSiteCostsAndContractManufacturing	524000	USD
CY2017Q3	ovas	Development Site Costs And Contract Manufacturing DevelopmentSiteCostsAndContractManufacturing	475000	USD
CY2013Q4	ovas	Ownership Control Percentage With Disputes Resolved Through Arbitration OwnershipControlPercentageWithDisputesResolvedThroughArbitration	0.5
	ovas	Proceeds From Issuance Of Common Stock From Share Based Compensation Plan Net Of Tax ProceedsFromIssuanceOfCommonStockFromShareBasedCompensationPlanNetOfTax	221000	USD
	ovas	Proceeds From Issuance Of Common Stock From Share Based Compensation Plan Net Of Tax ProceedsFromIssuanceOfCommonStockFromShareBasedCompensationPlanNetOfTax	0	USD
CY2017Q2	ovas	Restructuringand Related Cost Expected Numberof Positions Eliminated Percent RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent	0.50
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2183000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2691000	USD
CY2016Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	11026000	USD
CY2017Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	6212000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11026000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6212000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3428000	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4043000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-60000	USD
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-21000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	358419000	USD
CY2017Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	365226000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	607000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	101000	USD
CY2016Q4	us-gaap	Assets Assets	122543000	USD
CY2017Q3	us-gaap	Assets Assets	82025000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	116444000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	77607000	USD
CY2017Q3	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	300000	USD
CY2017Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	500000	USD
CY2017Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	200000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	114388000	USD
CY2017Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	75736000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	63000	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	21000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	114448000	USD
CY2017Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	75757000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	46600000	USD
CY2017Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	19500000	USD
CY2017Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	10000000	USD
CY2016Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	21	security
CY2017Q3	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	9	security
CY2017Q3	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	11	security
CY2017Q3	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	2	security
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43224000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50480000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43930000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24775000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	75700000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35641505	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35705722	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35641505	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35705722	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9340000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19322000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-59469000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42409000	USD
CY2016Q3	us-gaap	Cost Of Revenue CostOfRevenue	1559000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	3968000	USD
CY2017Q3	us-gaap	Cost Of Revenue CostOfRevenue	29000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	572000	USD
CY2017Q3	us-gaap	Deferred Compensation Arrangement With Individual Cash Award Granted Amount DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount	800000	USD
	us-gaap	Deferred Compensation Arrangement With Individual Requisite Service Period1 DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1	P18M
CY2016Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1645000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1600000	USD
CY2017Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	400000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1311000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1300000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.92
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.19
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5869000	USD
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3031000	USD
CY2013Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	1500000	USD
CY2013Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.5
CY2016Q4	us-gaap	Equity Method Investments EquityMethodInvestments	65000	USD
CY2017Q3	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2017Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	100000	USD
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	USD
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	250000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19199000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-59400000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9356000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42414000	USD
CY2016Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-364000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1171000	USD
CY2017Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-140000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1015000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	92000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	217000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	33000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-639000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	517000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1184000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-5440000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-543000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-635000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-197000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	350000	USD
CY2016Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	162000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	497000	USD
	us-gaap	Operating Expenses OperatingExpenses	59176000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	9462000	USD
	us-gaap	Operating Expenses OperatingExpenses	42126000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18964000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-58644000	USD
CY2017Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	193000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	560000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	116000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	102000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	14325000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	9737000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	122543000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82025000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13209000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8903000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	7256000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-19155000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54155000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-134000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18424000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46765000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37579000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-19291000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-59617000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-9367000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-42447000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	19161000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9406000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-41922000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2465000	USD
CY2017Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1539000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-31000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	148000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	27000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	38000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1116000	USD
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	834000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-33000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-82000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-37000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	5694000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	5700000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1800000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1750000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	600000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	550000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1045000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	112000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	65633000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	48403000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2017Q3	us-gaap	Restructuring Charges RestructuringCharges	400000	USD
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2056000	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1871000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	53934000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	45008000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	67839000	USD
CY2017Q3	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	300000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	23089000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9000000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7649000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5572000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3606000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4990000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16932000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4016000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14777000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	439000	USD
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	789000	USD
CY2017Q3	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1	9200000	USD
CY2016Q3	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2017Q3	us-gaap	Restructuring Charges RestructuringCharges	361000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3842000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3800000	USD
CY2016Q4	us-gaap	Restructuring Reserve RestructuringReserve	3406000	USD
CY2017Q3	us-gaap	Restructuring Reserve RestructuringReserve	1245000	USD
CY2017Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1200000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-250177000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-293000000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-292953000	USD
CY2016Q3	us-gaap	Revenues Revenues	197000	USD
	us-gaap	Revenues Revenues	532000	USD
CY2017Q3	us-gaap	Revenues Revenues	56000	USD
	us-gaap	Revenues Revenues	204000	USD
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12612000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38276000	USD
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5056000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.37
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22935000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8225000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6377000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.19
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.24
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	737500	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2224600	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	192500	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4207856	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.15
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.05
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.14
CY2017Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.40
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.51
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	70458000	USD
CY2017Q3	us-gaap	Short Term Investments ShortTermInvestments	50961000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	108218000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	72288000	USD
	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	300000	USD
	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.5
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35568000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30985000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35687000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35664000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of estimates and summary of significant accounting policies</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements are presented in conformity with US GAAP, which requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies,” in our 2016 Annual Report on Form 10-K.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the first quarter of 2017, we adopted Accounting Standard Update ("ASU") No. 2016-09 Compensation - Stock Compensation and have changed our accounting policy regarding the accounting for forfeitures and have elected to account for forfeitures as they occur. We adopted ASU 2016-09, using a modified retrospective approach and recorded a cumulative catch-up to increase retained earnings by approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> as of January 1, 2017.</font></div></div>

Files In Submission

Name	View Source	Status
0001544227-17-000014-index-headers.html	Edgar Link	pending
0001544227-17-000014-index.html	Edgar Link	pending
0001544227-17-000014.txt	Edgar Link	pending
0001544227-17-000014-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ovas-20170930.xml	Edgar Link	completed
ovas-20170930.xsd	Edgar Link	pending
ovas-20170930x10q.htm	Edgar Link	pending
ovas-20170930xex101.htm	Edgar Link	pending
ovas-20170930xex311.htm	Edgar Link	pending
ovas-20170930xex312.htm	Edgar Link	pending
ovas-20170930xex321.htm	Edgar Link	pending
ovas-20170930xex322.htm	Edgar Link	pending
ovas-20170930_cal.xml	Edgar Link	unprocessable
ovas-20170930_def.xml	Edgar Link	unprocessable
ovas-20170930_lab.xml	Edgar Link	unprocessable
ovas-20170930_pre.xml	Edgar Link	unprocessable
ovaskroegerinducement_image1.gif	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2017 Q4 Form 10-Q Financial Statement

#000154422717000014 Filed on November 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2017 Q4 Form 10-Q Financial Statement

#000154422717000014 Filed on November 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst